Assenagon Asset Management S.A. Has $776,000 Holdings in 4D Molecular Therapeutics, Inc. $FDMT

Assenagon Asset Management S.A. cut its holdings in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 71.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 83,333 shares of the company’s stock after selling 212,866 shares during the period. Assenagon Asset Management S.A.’s holdings in 4D Molecular Therapeutics were worth $776,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. RA Capital Management L.P. raised its position in 4D Molecular Therapeutics by 23.9% in the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after purchasing an additional 1,090,000 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of 4D Molecular Therapeutics by 164.4% during the fourth quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock worth $34,726,000 after purchasing an additional 2,882,508 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of 4D Molecular Therapeutics by 4.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,302,905 shares of the company’s stock valued at $32,272,000 after buying an additional 174,489 shares in the last quarter. State Street Corp increased its stake in shares of 4D Molecular Therapeutics by 197.5% in the fourth quarter. State Street Corp now owns 2,688,880 shares of the company’s stock valued at $20,167,000 after buying an additional 1,785,106 shares in the last quarter. Finally, Armistice Capital LLC increased its stake in shares of 4D Molecular Therapeutics by 76.6% in the fourth quarter. Armistice Capital LLC now owns 1,936,000 shares of the company’s stock valued at $14,520,000 after buying an additional 840,000 shares in the last quarter. 99.27% of the stock is owned by institutional investors and hedge funds.

4D Molecular Therapeutics Trading Up 2.4%

NASDAQ FDMT opened at $13.00 on Friday. 4D Molecular Therapeutics, Inc. has a 12 month low of $3.86 and a 12 month high of $14.00. The stock has a 50-day simple moving average of $9.81 and a 200 day simple moving average of $9.21. The company has a market capitalization of $679.59 million, a PE ratio of -5.06 and a beta of 2.70.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The company had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. As a group, sell-side analysts predict that 4D Molecular Therapeutics, Inc. will post -4.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 9,810 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total value of $117,720.00. Following the completion of the sale, the insider owned 8,617 shares of the company’s stock, valued at approximately $103,404. This represents a 53.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Kirn sold 114,746 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the completion of the sale, the insider directly owned 942,485 shares of the company’s stock, valued at $9,867,817.95. The trade was a 10.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 126,478 shares of company stock worth $1,338,369 over the last quarter. 7.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on FDMT shares. The Goldman Sachs Group set a $33.00 price target on shares of 4D Molecular Therapeutics in a research report on Friday, May 8th. Jefferies Financial Group restated a “buy” rating and issued a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Royal Bank Of Canada upped their target price on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a research report on Thursday, March 19th. Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Chardan Capital restated a “buy” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, 4D Molecular Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $29.88.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.